Valiant Organics, focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications, is planning to start production in Ortho Amino Phenol (OAP) and Pharma Intermediates in Q2 FY23.    

Ortho Amino Phenol (OAP) Phase 1 production will commence from Q2 FY23. Part of the production will be utilized as forward integration for one of the company's existing products. For OAP, the company has incurred a total Capex of Rs. 15 crore. The company has recently completed a successful trial run.

For Pharma Intermediates the expected production timeline is from Q2 FY23. This is a multi-purpose plant for forward integration within Group company and will manufacture N-1 and N-2 raw materials for API products. The company has incurred a total Capex Rs. 60 crore. 

Valiant Organics Limited, incorporated in 1984 by first generation technocrats, focuses on chemistries which include Chlorination, Hydrogenation, Ammonolysis, Acetylation, Sulphonation, and Methoxylation. Over the years the company has primarily focused on manufacturing specialty chemicals that have a high demand but low supply and are primarily dependent on imports. The company has a total production capacity of 70,000 TPA.

The company's Q1 FY23 financials were impacted primarily due to the unfortunate blast at our Chlorination plant in Sarigam leading to shutdown for an extensive period of time, as well as subdued demand of our hydrogenation products and mandatory maintenance shut down at Ammonolysis plant.